Blood is defined as entire human blood that has been obtained from a donor and processed for transfusion or further production. Blood component refers to a therapeutic component of human blood, including its red, white, platelet, and plasma cells. The blood and blood components market consist of sales of blood and blood component. The market involves the collection of donor's blood and segregating it into required components for the purpose of therapy. The main types of products in blood and blood components are whole blood and blood components. Human blood from a typical blood donation is known as whole blood. It is utilized in the treatment of excessive bleeding, exchange transfusions, and self-donation of blood. The different blood components include red blood cells, platelets, plasma, and white blood cells and are used in anemia, trauma and surgery, cancer treatment, and bleeding disorders. The several end-users involved are hospitals, ambulatory surgical centres, and others. The blood and blood components market research report is one of a series of new reports from The Business Research Company that provides blood and blood components market statistics, including blood and blood components industry global market size, regional shares, competitors with a blood and blood components market share, detailed blood and blood components market segments, market trends and opportunities, and any further data you may need to thrive in the blood and blood components industry. This blood and blood components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global blood and blood components market size will grow from $37.49 billion in 2022 to $39.21 billion in 2023 at a compound annual growth rate (CAGR) of 4.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global blood and blood components market size is expected to grow to $47.53 billion in 2027 at a CAGR of 4.9%. The blood and blood components market is being driven by increasing incidence of trauma and road accidents. Sometimes, because of traumas such as hemorrhage, the volume of blood is reduced to a very low level and cannot be replaced fast enough by the body. Also, road accidents cause excessive blood loss from the body that has to be restored immediately. At times, the blood itself lacks a few components as in the case of hemophilia. All these conditions demand transfusion of blood and blood components into the patient's body. The growing prevalence of diseases and increasing numbers of road accidents and traumas are increasing the demand for blood and thus driving the market. According to a report by Centres for Disease Control and Prevention, Hemophilia A affects one out of every 5,000 male babies born. Every year, about 400 newborns are born with haemophilia. Also, according to the Arizona Department of Health Services, in 2021, trauma related deaths increased by 19% as compared to 2020. Falls accounted for most deaths and injuries. The blood and blood components market is restrained by the growing risk of developing or transferring an infection while the blood is transmitted to the patients. The growing possibilities of developing any transfusion transmitted infection (TTI) is imposing a restriction on the growth of the market. The fear of transfusion of diseases from the donor to the recipient, forces many customers to avoid using donated blood, thus hampering the growth of the blood and blood components market. The most common viral agents that can be transmitted through blood transfusion are Human Immunodeficiency Virus (HIV), hepatitis viruses, West Nile Virus (WNV), Human T-cell Lymphotrophic Viruses (HTLVs). The most prominent trend that has been witnessed in the blood and blood components market is the growing number of collaborations between the players involved in the market. Companies are adopting partnerships and collaborations in order to expand their reach, increase customer base and generate awareness in the market. For example, the American Red Cross collaborated with HealthStream with an aim of introducing new program for healthcare organizations. Similarly, the BloodCenter of Wisconsin collaborated with SysLogic Inc., to study how the RFID technology can be used to enhance safety of the patient while collecting and transfusing blood products. The blood and blood components market in European Union is governed by Directive 2002/98/EC of the EU regulations. The regulatory body engages itself in providing guidelines and setting standards for quality and safety of collection, testing, processing, storage, and distribution of blood and blood components. These guidelines ensure greater quality and safety of whole blood and its components to prevent transmission of diseases and also highlight necessary measures for their collection and distribution. In October 2022, Pfizer, a US-based pharmaceutical company, acquired Global Blood Therapeutics for an undisclosed amount. The acquisition will strengthen Pfizer's capabilities in treating sickle cell disease while preserving the company's 30-year legacy.Global Blood Therapeutics is a US-based developer of treatments related to blood diseases, especially sickle cell disease.  Major players in the blood and blood components market are the American Red Cross, Australian Red Cross Blood Service, Abbott Laboratories, Blood Centres of America, Becton, Dickinson & Co., German Red Cross, Nipro Medical Corporation, American Association of Blood Banks, AVIS National, and National Blood Authority Australia. North America was the largest region in the blood and blood components market in 2022. Western Europe was the second largest region in the global blood and blood components market. The regions covered in the global blood and blood components market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the blood and blood components market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The blood and blood components market consist of sales of red cells, platelets, plasms, cryoprecipitated AHF, and granulocytes. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global blood and blood components market is segmented - 1) By Product: Whole Blood, Blood Components 2) By End-Users: Hospitals, Ambulatory Surgical Centers, Other End-Users 3) By Application: Anemia, Trauma & Surgery, Cancer Treatment, Bleeding Disorders 4) By Blood Components: Red Blood Cells, Platelets, Plasma, White Blood Cells

Blood cancer drugs refer to the drugs or medications that used to treat blood cancer drugs by using the body's immune system to fight blood cancer by slowing down the growth of cancer cells. Chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant are a few of the frequently used blood cancer treatments. The main types of blood cancer drugs are leukemia, and lymphoma. Leukemia is a blood-forming tissue cancer that affects the bone marrow and lymphatic tract. The different types of drugs include rituaxan/Mabthera (rituximab), Gleevec/Glivec (imatinib), Revlimid (lenalidomide), Velcade (bortezomib), Tasigna (nilotinib), pomalyst (pomalidomide), Fidanza (azacitidine), kyphosis (carfilzomib), advertise (brentuximabvedotin), others and involve various treatment approaches such as key findings, chemotherapeutic, mabs/targeted therapies, immunotherapeutic. The blood cancer drugs market research report is one of a series of new reports from The Business Research Company that provides blood cancer drugs market statistics, including blood cancer drugs industry global market size, regional shares, competitors with a blood cancer drugs market share, detailed blood cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the blood cancer drugs industry. This blood cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global blood cancer drugs market size will grow from $61.05 billion in 2022 to $66.17 billion in 2023 at a compound annual growth rate (CAGR) of 8.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global blood cancer drugs market size is expected to grow to $87.74 billion in 2027 at a CAGR of 7.3%. The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukemia, myeloma, and others have different risk factors where some can be controlled or prevented through drug therapies and others may lead to death. According to the Bristol-Myers Squibb Company report, over 1.85 million new blood cancer cases are expected to be diagnosed across the globe in 2040, out of which 918,872 cases are from lymphoma, 656,345 from leukemia, and 275,047 cases from myeloma. Furthermore, the report estimated, that in 2040, the approximate number of deaths worldwide due to blood cancer will be 1,100,000The increasing deaths and increasing incidence of blood cancer cases globally drive the blood cancer drug market. Drug approval involves a series of research stages and regulatory approvals that are often expensive. The drug approval process includes about four phases of clinical trials and various stages of the screening process with the regulatory body such as the FDA. The costs of failed clinical trials are also high as clinical trial phases involve huge investments. According to the Tufts Centre for the Study of Drug Development, the cost of bringing a new drug from its conception to shelves is about $2.7 billion. Thus, indicating that the high drug approval costs hinder the growth of the blood cancer drugs market. Companies in the blood cancer drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyze large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching blood cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major blood cancer drug manufacturers such as Roche, Pfizer, and Johnson and Johnson have already invested in AI technologies to reduce the time taken and costs incurred for drug development. For instance, Johnson and Johnson agreed with BenevolentAI, a UK-based artificial intelligence company (start-up), to mine data for designing new blood cancer drugs. The food and drug administration (FDA) is a federal agency regulating the blood cancer drugs market. FDA declined to approve Daiichi Sankyo’s leukemia drug for blood cancer treatment. Daiichi Sankyo, a global pharmaceutical company developing, importing, and marketing pharmaceutical products received a rejection notice on its drug - quizartinib used for treating adults with a type of blood cancer. The rejection of the drug was due to the negative impact caused after the intake which resulted in FDA's statement saying faulty application for blood cancer treatment in an internal review. To avoid the incidences caused by such medicines in treating medical conditions such as blood cancer, FDA has declined the approval. In July 2022, GSK, a UK-based pharmaceutical company acquired Sierra Oncology for an undisclosed amount. Through this acquisition, GSK company expands its oncology portfolio. Sierra Oncology is a US-based company that develops drugs for cancer including blood cancer. Major players in the blood cancer drugs market are Amgen Inc., AstraZeneca PLC., Bayer AG, Celgene Corporation, Eli Lilly, Johnson & Johnson, Novartis, Pfizer Inc., AbbVie Inc. and Takeda Pharmaceutical Company Ltd. North America was the largest region in the blood cancer drugs market in 2022. Middle East is expected to be the fastest-growing region in the global blood cancer drugs market during the forecast period. The regions covered in the blood cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the blood cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The blood cancer drugs market consists of sales Altretamine, Bendamustine, Bendamustine, and Carboplatin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global blood cancer drugs market is segmented - 1) By Blood Cancer Type: Leukemia, Lymphoma 2) By Drugs: Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Other Drugs 3) By Treatment Approaches: Key Findings, Chemotherapeutic, mAbs/Targeted Therapies, Immunotherapeutic

Blood group typing is a method that tells the type of blood a person has, and it is done so that a person can safely donate blood or receive a blood transfusion. The main types of blood group typing are antibody screening, cross-matching tests, ABO tests, antigen typing and human leukocyte antigen (HLA) typing. The antibody screening tests are performed in a clinical laboratory or blood bank is done to detect the presence of unexpected antibodies, like alloantibodies in the serum to antigens of the non-ABO blood group system. Cross-matching tests are performed before a blood transfusion as part of blood compatibility testing. Human leukocyte antigen (HLA) typing is a kind of genetic test used to identify certain individual variations or proteins in the immune system. It is often used to match patients and donors for bone marrow or cord blood transplants. ABO tests are done to evaluate the blood type of a person out of four types, which are A, B, AB, or O.  Antigen tests are immunoassays that are used to detect the presence of a specific viral antigen and are commonly used in the diagnosis of respiratory pathogens, including influenza viruses and respiratory syncytial virus. The products that are used for blood group typing are instruments, reagents, and kits, and the techniques that are used are serology tests, and molecular tests. Blood group typing is used in hospital-based laboratories, independent laboratories, and blood banks. The blood group typing market research report is one of a series of new reports from The Business Research Company that provides blood group typing market statistics, including  blood group typing industry global market size, regional shares, competitors with a  blood group typing market share, detailed  blood group typing market segments, market trends and opportunities, and any further data you may need to thrive in the  blood group typing industry. This blood group typing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global blood group typing market size grew from $2.4 billion in 2022 to $2.7 billion in 2023 at a compound annual growth rate (CAGR) of 12.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The blood group typing market size is expected to grow to $4.29 billion in 2027 at a CAGR of 12.2%. The increase in number of blood donations and transfusions drove the blood group typing market during the historic period. Different non-profit organizations, government organizations and other agencies are emphasizing the importance of blood donations and transfusions and spreading awareness through various campaigns. An increase in blood donations increased the demand for blood group typing so that the donor can know what type of blood they have. For instance, according to a report by the WHO in 2022, in high-income nations, which are home to 16% of the world's population, blood donations account for 40% of the 118.5 million donations that are made worldwide. Moreover, children under the age of five receive up to 54% of blood transfusions in low-income nations, compared to patients over 60 who receive up to 76% of transfusions in high-income countries. The increase in the number of blood donations and transfusions thereby contributed to the growth of the blood typing market. Technological advancements such as automated technologies for blood typing gaining traction in the blood group typing market. Major companies in the market are focusing on introducing new types of tests based on innovative techniques that offer results in low turn-around time, with improved accuracy and efficiency. In September 2021, Ortho Clinical Diagnostics, a US-based in vitro diagnostics company, launched Immediate Spin Crossmatch (ISXM). ISXM is a serological test used in blood transfusions to identify ABO blood type mismatch between donor red blood cells and receiver serum or plasma. This new menu feature expands Ortho's complete automated testing offering with the addition of ISXM.  In October 2020, Calibre Scientific, a provider of life science reagents, tools, instruments?and other consumables to the lab research, diagnostics, industrial and biopharmaceutical communities, acquired Lorne Laboratories for an undisclosed amount. The acquisition will support the Calibre diagnostics division and expand the expertise of the company. Lorne Laboratories is a speciality manufacturer of blood grouping reagents and diagnostic test kits. Major players in the the blood group typing market are Grifols, Bio-Rad Laboratories, Immucor Inc., Ortho Clinical Diagnostics, Quotient, BAG Health Care GmbH, AXO Science, Agena Bioscience, Merck KGaA, Beckman Coulter Inc., Sucuri Inc., Rapid Labs, AXO Science, Day Medical SA, and Novacyt Group. North America was the largest region in the blood group typing market in 2022. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the blood group typing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the blood group typing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The blood group typing market consists of sale of serology reagents, gel systems, lateral flow rapid technology, and blood group genotyping products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global blood group typing market is segmented - 1) By Test Type: Antibody Screening, Cross-Matching Tests, ABO Tests, Antigen Typing, HLA Typing 2) By Product: Instruments, Reagents And Kits 3) By Techniques: Serology Tests, Molecular Tests 4) By End User: Hospital Based Laboratories, Independent Laboratories And Blood Banks

Blood glucose meters are devices that are used to measure and display the amount of sugar (glucose) in the blood. The main product types of blood glucose meters market are electrode type blood glucose meter and the photoelectric blood glucose meter. Electrode type blood glucose meters are devices that contain electrodes to measure the current generated by an enzymatic reaction between glucose, an enzyme, and a mediator. The various applications included are type 1 diabetes, type 2 diabetes, and gestational diabetes, which are used by various end-users such as hospitals and home care. The blood glucose meters market research report is one of a series of new reports from The Business Research Company that provides blood glucose meters market statistics, including blood glucose meters industry global market size, regional shares, competitors with a blood glucose meters market share, detailed blood glucose meters market segments, market trends and opportunities, and any further data you may need to thrive in the blood glucose meters industry. This blood glucose meters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global blood glucose meters market size will grow from $15.64 billion in 2022 to $16.96 billion in 2023 at a compound annual growth rate (CAGR) of 8.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The blood glucose meters market size is expected to grow to $22.34 billion in 2027 at a CAGR of 7.1%. The rising prevalence of diabetes is driving the blood glucose meters market. The changing lifestyle, increase in alcohol consumption, physical inactivity, and unhealthy eating habits are leading to an increase in obesity across the globe. Such exponential growth in obese people is causing a stern increase in the purchase of blood glucose meters. Due to obesity, fat tissues release more fat molecules into the blood affecting insulin-responsive cells, which results in reduced insulin sensitivity, in turn, causing diabetes. According to the study by the International Diabetes Federation (IDF), there will be a 48% increase in diabetes around the world by 2045. According to the International Diabetes Federation (IDF) in 2021, nearly 537 million people were suffering from diabetes. The blood glucose meters market growth is restricted due to a lack of awareness of diabetes. Hypo unawareness is a common term used to describe people who have diabetes, especially type 1 diabetes, it is very difficult to notice when they have low blood glucose, hypoglycemia. Such lack of awareness of diabetes and its effects reduces the regular monitoring or check-ups relating to diabetes. For example, in 2021, 537 million adults had diabetes, but more than 1 in 4 did not know that they had the disease. Also, in 2021, According to the International Diabetes Federation (IDF), over one in two (54%) patients with diabetes do not recognize that they have diabetes. The launch of new products is a key trend gaining popularity in the blood glucose meters market. Companies in the market are focusing on the launch of new products to improve their product portfolio and strengthen their market position. For example, in January 2022, Roche, a Swiss multinational healthcare company, launched its new point-of-care blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that will run its own apps. Glytec, a US based insulin management software company supplied software for the device, its Glucommander insulin-dosing program to help streamline the complex task of managing blood sugar levels during a patient's hospital stay. FDA regulates blood glucose meters. FDA has released its guidance for the accuracy of blood glucose meters. For blood glucose meters used in the home by patients with diabetes, FDA states that 95% of the measured blood glucose levels should be within 15% of the lab tested value and 99% of the measured values should be within 20% of the lab tested value. For the point of care blood glucose monitoring devices, 95% of the monitored values must be within the range of 12% for blood sugars more than 75mg/dl and must be within 12mg/dl for blood sugars less than 75mg/dl. Also, 98% of the meter values must be within 15% of the range for blood sugars more than 75mg/dl and must be within 15mg/dl for blood sugars less than 75mg/dl. In September 2021, B. Braun Melsungen AG, a German medical and pharmaceutical device company acquired Sterinova Inc for an undisclosed amount. This acquisition of Sterinova will continue to operate as a distinct subsidiary of B. Braun Melsungen AG. Sterinova Inc is a Canada-based company that develops, manufactures, and distributes ready-to-use sterile injectable products in syringes and premix bags. Major players in the blood glucose meters market are Abbott, Roche, Medtronics, Ascensia, Dexcom, Johnson & Johnson, Arkray, Acon, LifeScan, and Agamatrix Inc. North America was the largest region in the global blood glucose meters market in 2022. Western Europe was the second-largest region in the blood glucose meters market. The regions covered in the global blood glucose meters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries in the blood glucose meters market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The blood glucose meters consist of sales of electrode-type blood glucose meter and photoelectric blood glucose meter. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global blood glucose meters market is segmented - 1) By Product type: Electrode Type Blood Glucose Meter, Photoelectric Blood Glucose Meter 2) By End User: Hospitals, Home Care 3) By Application: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes

Blood transfusion diagnostics are used to conduct tests before the transfusion of blood from donor-recipient such as blood grouping disease screening. The main types of blood transfusion diagnostics are instruments and kits, reagents, and others. The blood transfusion diagnostic kits are used to collect and transfuse blood. The technologies involved in blood transfusion diagnostics are western blot, ELISA, nucleic acid amplification, fluorescence assay, and rapid test that are used for various applications such as blood grouping and disease screening. The end-users involved are hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies. The blood transfusion diagnostics market research report is one of a series of new reports from The Business Research Company that provides blood transfusion diagnostics market statistics, including blood transfusion diagnostics industry global market size, regional shares, competitors with a blood transfusion diagnostics market share, detailed blood transfusion diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the blood transfusion diagnostics industry. This blood transfusion diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global blood transfusion diagnostics market grew from $3.65 billion in 2022 to $3.98 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The blood transfusion diagnostics market is expected to grow from $5.68 billion in 2027 at a CAGR of 9.3%. Patients undergoing surgical procedures need a blood transfusion to replace the lost blood during the procedure. Blood transfusion diagnostics are used during the procedures to screen the blood before transferring it to the patient and will otherwise increase the incidence of infectious disease. According to an article published in the US National Library of Medicine, National Institutes of Health, approximately 310 million surgeries are being performed each year. This increase in the number of procedures will thereby drive the need for blood transfusion diagnostics. Developing and underdeveloped countries lack adequate blood banks, proper medical equipment for blood transfusion, adequate conditions for the storage of blood, and low supply for the high demand of blood. Hospitals are not equipped with proper amenities that help provide hygienic and safe transfusions. For example, according to research conducted by India Spend, around 1.18 million units of blood were wasted during storage in the form of discoloration, bacterial contamination, and expiry due to outdating. The poor infrastructure hampers the growth of the blood transfusion diagnostic market. The growing demand for advanced diagnostic measures and growing prevalence of infectious diseases associated with pathogens such as bacteria & viruses increase the preference for nucleic acid amplification testing (NAAT/NAT) to increase blood safety, improve efficiency and reduce the turnaround time of the results. NAT is a technique that helps detect a particular nucleic acid, virus, or bacteria that acts as a pathogen in blood, tissue, or urine. NAT is highly sensitive and specific for viral nucleic acids and amplifies the region of targeted viral DNA and detects them earlier than the other traditional methods and narrows the period of infectious diseases. For example, XCRP Diagnostic Inc. and Luminex Corporations entered into a licensing agreement of XCR Diagnostic's Xtreme Chain Reaction Nucleic Acid Amplification Technology. In this deal, Luminex got the exclusive rights to use the XCR Diagnostic's NAAT technology for their future molecular diagnostic portfolio. The blood transfusion diagnostics market is highly regulated by governing bodies such as USFDA (the USA Food and Drug Administration), and the Medicines and Healthcare products Agency (MHRA). For instance, the manufacturers and service providers in the USA must comply with the Center for Biologics Evaluation and Research (CBER) Regulations that have been published in the first chapter title 21 of the Code of Federal Regulations (CFR). Part 600 of CFR 21 primarily focuses on the established standards like retention samples conditions, temperature to be maintained during shipment, sterilization of equipment, and role and duties of the inspector to inspect the laboratories. The regulation also allows the manufacturer to report any kind of deviation of their product from their intended purpose. Major players in the blood transfusion diagnostics market are BAG Health Care GmbH, Grifols, Bio-Rad Laboratories Inc., Abbott Laboratories, Immucor Inc., Ortho Clinical Diagnostics, DiaSorin S.p.A, Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc., and Beckman Coulter Inc. North America was the largest region in the blood transfusion diagnostics market in 2022. Western Europe was the second largest region in the global blood transfusion diagnostics market. The regions covered in global blood transfusion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the blood transfusion diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The blood transfusion diagnostics market consists of revenues earned by entities by providing installation and maintenance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood transfusion diagnostics market also includes sales of blood transfusion diagnostics devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global blood transfusion diagnostics market is segmented - 1) By Type: Instruments and Kits, Reagents, Other Types 2) By End User: Hospitals, Diagnostic Laboratories, Blood Banks, Plasma Fractionation Companies 3) By Technology: Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test 4) By Application: Blood Grouping, Disease Screening

Blood collection devices are devices used to collect blood samples from the body. Blood collection devices are used for health and wellness testing, population studies, or research and preclinical drug studies. The main types of blood collection devices include blood collection tubes, lancets, micro container tubes, and warming devices. The blood collection tubes refer to tubes used for coagulation investigations and sodium citrate-containing blood collection. Blood collection tubes are used for various components and conduct blood into and out of a patient’s body to get tested in the laboratory. Different tests and biochemical assays require various types of sample collection tubes. The different materials used in the manufacturing of blood collection devices include glass, stainless steel, and plastic. They are used in manual and automatic blood collection by hospitals, blood collection centers, diagnostic centers, and others. The blood collection devices market research report is one of a series of new reports from The Business Research Company that provides blood collection devices market statistics, including blood collection devices industry global market size, regional shares, competitors with a blood collection devices market share, detailed blood collection devices market segments, market trends and opportunities, and any further data you may need to thrive in the blood collection devices industry. This blood collection devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global blood collection devices market size grew from $6.92 billion in 2022 to $7.39 billion in 2023 at a compound annual growth rate (CAGR) of 6.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The blood collection devices market size is expected to grow to $9.59 billion in 2027 at a CAGR of 6.8%. The increase in incidence of infectious diseases is driving the growth of the blood collection devices market. Infectious diseases are infections caused by bacteria, viruses, fungi, or parasites. Infectious disorders such as hepatitis B (HBV), hepatitis C (HCV), the human immunodeficiency virus (HIV), malaria, syphilis, and brucellosis are tested through blood collection and sampling. The constant increase in incidences of infectious diseases and its diagnostics activities are expected to boost the utilization of blood collection devices. According to World Health Organization (WHO), in 2021, an estimated 10.6 million people are infected with tuberculosis globally, 1.6  million died, and 1.5 million people acquired HIV in 2021 while 650,000 people lost lives due to it. Therefore, the increase in incidences of infectious diseases is expected to boost demand for blood collection devices during the forecast period. Technology advancement is a key trend gaining popularity in the blood collection devices market. Many companies operating in the blood collection devices market are developing new products or new technologies to meet fast-growing industry demand and enhance their business presence across the globe. The technologically advanced products developed by companies are focused on enhancing comfort and providing advanced protection to customers. For instance, in April 2022, Owen Mumford, a medical device design and manufacturing company, introduced a new venous blood collection portfolio under its Unistik brand. The new portfolio draws on the company's expertise and history in capillary blood sampling to provide a range of venous devices that ensure patient safety, comfort, and quality. The Unistik ShieldLock Ultra combines a one-handed and in-vein activated safety system to reduce the risk of NSIs. The device also has a unique safety feature that, when activated, closes the tube between the needle and the Luer to avoid blood exposure after the needle is removed from the vein. In July 2021, a leading global medical technology company Becton, Dickinson and Company (BD) acquired Velano Vascular for an undisclosed amount. With this acquisition, BD enables health care providers to help eliminate multiple needlesticks for blood sample collection, reducing the pain and discomfort from the process while delivering quality outcomes and increasing patient satisfaction. Velano Vascular is a US-based medical equipment manufacturer committed to enhancing both inpatient blood collection and vascular access. Major players in the blood collection devices market are Becton, Dickinson and Company, Greiner Group, Kabe Labortechnik GmbH, Sarstedt AG & Company, ICU Medical Inc., Grifols SA, Retractable Technologies Inc., Nipro Corporation, Terumo Corporation, Fresenius Kabi AG, Medtronic, and Radiometer Medical ApS. North America was the largest region in the blood collection devices market in 2022. The Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood collection devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the blood collection devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The blood collection devices market consists of sales of blood collection tubes, needles and syringes, blood bags, blood collection systems, and lancets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global blood collection devices market is segmented - 1) By Type: Blood Collection Tubes, Lancet, Micro Container Tubes, Warming Devices 2) By Method: Manual Blood Collection, Automatic Blood Collection 3) By Material: Glass, Stainless Steel, Plastic 4) By End User: Hospitals, Blood Donation Centers, Diagnostic Center, Other End Users

Dialysis devices and equipment are used to filter a patient’s blood by removing waste products such as urea, creatinine, and excess water when kidneys fail or are damaged, dysfunctional, or missing. The main products of dialysis devices and equipment are hemodialysis devices and peritoneal dialysis devices. Hemodialysis is a process where a dialysis machine and a special filter called an artificial kidney, or a dialyzer, are used to clean the blood. The various applications involved are serum and blood treatment, virus purification, drug binding studies, and others. The various end-users are hospitals, clinics, ambulatory surgical centres, and home care settings. The dialysis devices and equipment market research report is one of a series of new reports from The Business Research Company that provides dialysis devices and equipment market statistics, including dialysis devices and equipment industry global market size, regional shares, competitors with a dialysis devices and equipment market share, detailed dialysis devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the dialysis devices and equipment industry. This dialysis devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global dialysis devices and equipment market size will grow from $4.72 billion in 2022 to $5.01 billion in 2023 at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The dialysis devices and equipment market size is expected to grow to $6.12 billion in 2027 at a CAGR of 5.1%. The increasing prevalence of kidney failure is driving the market for dialysis devices and equipment. The main purpose of dialysis devices and equipment is to artificially filter the blood to get rid of any toxins in the blood and to prevent such waste products from reaching hazardous levels. Chronic kidney disease (CKD) is a condition in which the kidneys are damaged and cannot filter the blood. According to the National kidney Foundation, in 2021, kidney disease affects 37 million people in the US and 90% of the patients are unaware about it. 2 in 5 adults who had serious kidney disease didn’t know that they had it. Product recalls have been the major restraint in the dialysis devices and equipment market. Product recalls are actions taken by organizations or any regulatory authority like US FDA to remove a product or device from the market. The dialysis devices and equipment are removed from the market when they fail to perform the functions for which they were manufactured. For example, B. Braun Medical Inc. recalls Dialog hemodialysis systems due to defective conductivity sensors. This machine is used in the treatment of chronic kidney disease for patients whose kidneys are no longer healthy enough to filter the blood to get rid of the wastes and excess fluid. Similarly, the Dialyzer, a device by the Fresenius Medical Care group was recalled due to the invalid message shown on the equipment when the Sustained low-efficiency Dialysis (SLED) program is used. The latest trend in the dialysis devices and equipment market is the use of technology to develop innovative products that can enhance functionality. To enhance the quality of the devices, new methods are being developed to speed up the process of filtering the blood and improve the overall filtration process. As a result of improved technology products like Revaclear High-Flux Dialyzer by Baxter, which enhances the filtration process of the blood by improving the speed at which the blood is filtered are being developed. Revaclear dialyzers are devices that can help detect renal failure by hemodialysis. With the improvement in technology, innovations in the devices are expected to continue. In April 2022, Baxter International received FDA clearance for its ST Set in-hospital dialysis machine. The company had filed an emergency use authorization request back in August 2020. Such approvals by FDA positively impact the global dialysis devices market. In September 2022, W.L. Gore & Associates, a US-based material science company, acquired InnAVasc Medical for an undisclosed amount. The acquisition strengthens the company’s ambition to improve the patients’ lives and providing innovative treatment to them. InnAVasc is a US-based medical technology company developing treatment to ease the dialysis patients. Major players in the dialysis devices and equipment market are Fresenius Medical Care AG & Co. KGaA, Baxter International, Nikkiso Co. Ltd., DaVita Inc., B. Braun Avitum AG, NxStage Medical, Asahi Kasei Corporation, Diaverum Deutschland GmbH, Medivators Inc., and Nipro Corporation. Asia-Pacific was the largest region in the global dialysis devices and equipment market in 2022. North America was the second largest market in dialysis devices and equipment market. The regions covered in the global dialysis devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the dialysis devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The dialysis devices and equipment market consist of sales of instruments such as dialyzers, dialysis pumping machines, blood pumps, catheters, and tubing kits that are used for dialysis. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global dialysis devices and equipment market is segmented - 1) By Product: Hemodialysis Devices, Peritoneal Dialysis Devices 2) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings 3) By Application: Serum And Blood Treatment, Virus Purification, Drug Binding Studies, Other Applications

Hemodialysis and peritoneal dialysis are used to eliminate waste products and excess fluids such as urea and creatinine from the blood by redirecting blood to a machine for the cleaning process. Hemodialysis refers to a treatment in which the blood is cleaned using a dialysis machine and a specific filter known as an artificial kidney, or dialyzer. It is a type of dialysis that uses the patient's own bodily tissues inside the abdominal cavity as a filter.  The main types of hemodialysis and peritoneal dialysis are hemodialyses, short-term catheters, chronic catheters, graft, fistula, and peritoneal dialysis. Hemodialysis refers to a procedure where a dialysis machine and a special filter called an artificial kidney, or a dialyzer, are used to clean the blood. The modality is conventional and daily (day time, night time). The end-users involved are hospitals, clinics, dialysis centers, and home dialysis. The hemodialysis and peritoneal dialysis market research report is one of a series of new reports from The Business Research Company that provides hemodialysis and peritoneal dialysis market statistics, including hemodialysis and peritoneal dialysis industry global market size, regional shares, competitors with a hemodialysis and peritoneal dialysis market share, detailed hemodialysis and peritoneal dialysis market segments, market trends and opportunities, and any further data you may need to thrive in the hemodialysis and peritoneal dialysis industry. This hemodialysis and peritoneal dialysis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hemodialysis and peritoneal dialysis market size grew from $73.86 billion in 2022 to $80.17 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hemodialysis and peritoneal dialysis market size is expected to grow to $110.29 billion in 2027 at a CAGR of 8.3%. The growing prevalence of kidney diseases is expected to propel the growth of the hemodialysis and peritoneal dialysis market going forward. Kidney disorders refer to a heterogeneous group of disorders that affect the structure and function of the kidney. Advanced chronic renal disease can result in dangerously high amounts of fluid, electrolytes, and wastes in the body, hemodialysis and peritoneal dialysis are used in the treatment in which the blood is cleaned using a dialysis machine and a specific filter known as an artificial kidney. For instance, in 2021, according to the Centers for Disease Control and Prevention’s report on chronic kidney disease, a US-based national public health agency, around 15% of US adults, or 37 million people, are estimated to have chronic kidney diseases. Therefore, the growing prevalence of kidney diseases is driving the hemodialysis and peritoneal dialysis market. Technological advancements are a key trend gaining popularity in hemodialysis and peritoneal dialysis. Major companies operating in the hemodialysis and peritoneal dialysis market are focused on developing new technological solutions to strengthen their position. For instance, in April 2022, Kuleana Technology, Inc., a Seattle-based startup focused on improving renal replacement therapies, got the first dialysis funding from the National Kidney Foundation (NKF) Innovation Fund. Kuleana is creating revolutionary portable hemodialysis equipment that does not need to be connected to an external water supply and won't need complicated sorbents. Due to the ability to dialyze while on the go, this device will be more efficient than existing dialysis, enabling whenever and wherever dialysis for millions of patients globally. In March 2021, DaVita Kidney Care, a US-based company that treats patients with chronic kidney failure and end-stage kidney disease, extended in collaboration with Fresenius Medical Care. The collaboration offers DaVita patients home hemodialysis technology across the United States, including NxStage machines, supplies, and a connected health platform. The cooperation helps both businesses achieve their objectives of encouraging more patients to select home dialysis, which can improve the quality of life for those with chronic kidney failure. Fresenius Medical Care is a US-based company specializing in kidney care. Major players in the hemodialysis and peritoneal dialysis market are Baxter International Inc., Nipro Corporation, B Braun Melsungen AG, Nikkiso Co. Ltd., Becton Dickinson And Company, Medtronic PLC, Asahi Kasei Corp., DaVita Inc., Diaverum, Cook Group Incorporated, Angiodynamics, Toray Medical Co. Ltd., Drägerwerk AG And Co. KGAA, and Cantel Medical Corporation. North America was the largest region in the hemodialysis and peritoneal dialysis market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemodialysis and peritoneal dialysis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the hemodialysis and peritoneal dialysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The hemodialysis and peritoneal dialysis market includes revenues earned by entities by n-centerhemodialysis, home hemodialysis, and peritoneal dialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.  The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global hemodialysis and peritoneal dialysis market is segmented - 1) By Type: Hemodialysis, Short-Term Catheter, Chronic Catheter, Graft, Fistula, Peritoneal Dialysis 2) By Modality: Conventional, Daily (Day Time, Night Time) 3) By End User: Hospitals, Clinics, And Dialysis Centers, Home Dialysis